Usefulness of Immunohistochemistry for the Detection of BRAFV600E Mutation in Papillary Thyroid Carcinoma. Comparison with Three Molecular Biology Methods (Dideoxy Sequencing, Pyrosequencing and SNaPshot)
Sandra Lassalle, Marius Ilie, Veronique Hofman, Christelle Bonnetaud, Olivier Bordonne, Aude Lamy, Jean-Christophe Sabourin, Juliette Haudebourg, Catherine Butori, Isabelle Peyrottes, Jean-Louis Sadoul, Alexandre Bozec, Jose Santini, Paul Hofman. Pasteur Hospital, Nice, France; CHU de Rouen, Rouen, France; Antoine Lacassagne Centre, Nice, France; Archet Hospital, Nice, France
Background: Several molecular biology technologies are available for the detection of BRAFV600E mutation in papillary thyroid carcinoma (PTC). The use of immunohistochemistry (IHC) as an alternative approach of these technologies for detection of BRAFV600E in PTC has not been evaluated until now.
Design: BRAFV600E mutation was analyzed by dideoxy sequencing, pyrosequencing and SNaPshot methods in 198 frozen PTC samples. Detection of the BRAFV600E mutation was performed by IHC using the VE1 clone antibody and compared to results of molecular methodologies. Consensus mutation was used as a reference test to calculate each parameter. Consensus mutations were defined as those detected at two or more of the four methods.
Results: 150/198 (75%) of the conventional PTC harbored a BRAFV600E mutation when using the SNaPshot and Pyrosequencing. 141/198 (71%) of the PTC showed a BRAFV600E mutation using dideoxy sequencing. IHC VE1 assay was positive in 145/150 (96%) BRAFV600E mutated tumors.
Conclusions: IHC using the VE1 clone is a specific and sensitive method for the detection of BRAFV600E and may be an alternative to molecular biology for detection of mutations in PTC.
Monday, March 4, 2013 1:15 PM
Proffered Papers: Section H, Monday Afternoon